{
    "id": 2999,
    "name": "granulosa cell tumor",
    "source": "DOID",
    "definition": "An ovarian cancer that has_material_basis_in granulosa cells and arises from the sex cord stroma. [url:https\\://en.wikipedia.org/wiki/Granulosa_cell_tumour]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "5333"
    ],
    "termId": "DOID:2999",
    "evidence": [
        {
            "id": 5775,
            "approvalStatus": "Preclinical",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "FOXL2 C134W mutations are used in the diagnosis of adult granulosa cell tumors of the ovary (PMID: 26791928, PMID: 22240241).",
            "molecularProfile": {
                "id": 3836,
                "profileName": "FOXL2 C134W"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 2999,
                "name": "granulosa cell tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5151,
                    "pubMedId": 26791928,
                    "title": "Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26791928"
                },
                {
                    "id": 5208,
                    "pubMedId": 22240241,
                    "title": "Molecular pathogenesis of granulosa cell tumors of the ovary.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22240241"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11452,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with ovarian granulosa cell tumor cancer harboring subclonal AKT E17K demonstrated an overall tumor regression of 24% when treated with AZD5363, which lasted 253 days (PMID: 28489509).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 2999,
                "name": "granulosa cell tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9361,
                    "pubMedId": 28489509,
                    "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28489509"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20713,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, STM 434 treatment did not result in response in 30 evaluable patients with advanced solid tumors and only resulted in stable disease as best response in 80% (10/12) of patients with granulosa cell ovarian cancer (PMID: 31068369; NCT02262455).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9438,
                "therapyName": "STM434",
                "synonyms": null
            },
            "indication": {
                "id": 2999,
                "name": "granulosa cell tumor",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 18011,
                    "pubMedId": 31068369,
                    "title": "First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31068369"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT03909152",
            "title": "A Study of Onapristone ER in Gynecologic Cancers That Respond to Progesterone",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1886,
                    "therapyName": "Onapristone",
                    "synonyms": null
                }
            ]
        }
    ]
}